Invesco
IMDX

Invesco’s Insight Molecular Diagnostics IMDX Stock Holding History

Invesco’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,083
Closed -$32K – 4108
2022
Q1 		$32K Buy
1,083
+13
+1% +$416 ﹤0.01% 3960
2021
Q4 		$46K Sell
1,070
-24
-2% -$1.38K ﹤0.01% 3988
2021
Q3 		$78K Buy
1,094
+151
+16% +$13.9K ﹤0.01% 3968
2021
Q2 		$108K Sell
943
-728
-44% -$71.1K ﹤0.01% 3881
2021
Q1 		$173K Buy
1,671
+115
+7% +$10.9K ﹤0.01% 3700
2020
Q4 		$74K Buy
+1,556
New +$57.1K ﹤0.01% 3688

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Invesco's IMDX Position: Q2 2022 in Review

Invesco sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 1,083 shares — an estimated $32K sold.

Invesco first reported a position in IMDX in Q4 2020 and held it in 6 quarters. The position peaked at $173K in Q1 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • Invesco reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Invesco sold 1,083 Insight Molecular Diagnostics shares in Q2 2022, an estimated $32K.
  • Invesco first reported a position in Insight Molecular Diagnostics in Q4 2020 and held it in 6 quarters.
  • Invesco's Insight Molecular Diagnostics position peaked at $173K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Invesco's 13F filing for Q2 2022, filed 15 Aug 2022.